ArticleBlood advances2026
Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractTreatment-free remission (TFR) is a major therapeutic goal in chronic myeloid leukemia. This study analyzed 5-year follow-up data and immune profiling from 2 independent phase 2 trials conducted by the Japan Adult Leukemia Study Group (JALSG), N-STOP216 (nilotinib [NIL], n = 51) and D-STOP216 (dasatinib [DAS], n = 49), involving patients who discontinued frontline second-generation (2G)-tyrosine kinase inhibitors (TKIs) after sustaining deep molecular response for ≥2 years. Both trials successfully met their primary end points, with 12-month TFR rates of 76.5% and 55.1% in the NIL and DAS trials, respectively. No disease progression was observed, confirming the safety of this strategy. The 5-year treatment-free survival (TFS) rates were 68.6% and 50.9% for NIL- and DAS-treated patients, respectively. Although recurrent cases in both cohorts rapidly regained a molecular response, NIL-treated patients showed a more gradual molecular recurrence and a persistent gap between TFS and event-free survival, suggesting relatively stable immune surveillance. Comparative immune profiling, although exploratory, suggested an "immune paradox" in the DAS cohort, characterized by expansion of effector memory T cells and mature CD57+ CD56dim natural killer cells alongside depletion of the "immune reservoir" of naïve and central memory cells. In the D-STOP trial, the retreatment group showed higher levels of effector regulatory T cells and exhausted CD4+ T cells compared with the TFR group. Furthermore, elevated prediscontinuation interleukin-1β (IL-1β) and IL-6 levels were associated with molecular relapse. These findings suggest that 2G-TKI-specific off-target effects influence TFR sustainability by modulating the immune microenvironment and the CD4+ helper cell status. The trials were registered at www.umin.ac.jp as UMIN000024984 (JALSG N-STOP216) and UMIN000024985 (JALSG D-STOP216).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.